Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy by Ocáriz-Díez, M. et al.
MINI REVIEW
published: 24 September 2020
doi: 10.3389/fonc.2020.568939
Frontiers in Oncology | www.frontiersin.org 1 September 2020 | Volume 10 | Article 568939
Edited by:
Kartik Sehgal,
Beth Israel Deaconess Medical Center




New York University, United States
Marcello Tiseo,





This article was submitted to
Thoracic Oncology,
a section of the journal
Frontiers in Oncology
Received: 17 June 2020
Accepted: 26 August 2020
Published: 24 September 2020
Citation:
Ocáriz-Díez M, Cruellas M, Gascón M,
Lastra R, Martínez-Lostao L,
Ramírez-Labrada A, Paño JR,
Sesma A, Torres I, Yubero A, Pardo J,
Isla D and Gálvez EM (2020)
Microbiota and Lung Cancer.




Microbiota and Lung Cancer.
Opportunities and Challenges for
Improving Immunotherapy Efficacy
Maitane Ocáriz-Díez 1,2*, Mara Cruellas 1,2, Marta Gascón 1,2, Rodrigo Lastra 1,2,
Luis Martínez-Lostao 2,3,4,5,6, Ariel Ramírez-Labrada 7, José Ramón Paño 2,8,
Andrea Sesma 1,2, Irene Torres 1,2, Alfonso Yubero 1,2, Julián Pardo 2,9,10,11, Dolores Isla 1,2 and
Eva M. Gálvez 12
1Medical Oncology Department, Lozano Blesa University Clinical Hospital, Zaragoza, Spain, 2 Instituto de Investigación
Sanitaria Aragón (IIS Aragón), Zaragoza, Spain, 3 Inmunology Department, Lozano Blesa University Clinical Hospital,
Zaragoza, Spain, 4Department of Microbiology, Pediatrics, Radiology and Public Health, University of Zaragoza, Zaragoza,
Spain, 5 Aragon Nanoscience Institute, Zaragoza, Spain, 6 Aragon Materials Science Institute, Zaragoza, Spain, 7Unidad de
Nanotoxicología e Inmunotoxicología (UNATI), Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), Biomedical
Research Centre of Aragón (CIBA), Zaragoza, Spain, 8 Infectious Diseases Department, Lozano Blesa University Clinical
Hospital, Zaragoza, Spain, 9 ARAID Foundation (IIS Aragón), Zaragoza, Spain, 10Microbiology, Preventive Medicine and
Public Health Department, Medicine, University of Zaragoza, Zaragoza, Spain, 11Biomedical Research Center in
Bioengineering, Biomaterials and Nanomedicine Network (CIBER-BBN), Madrid, Spain, 12 Instituto de Carboquimica
(ICB-Consejo Superior de Investigaciones Cientificas), Zaragoza, Spain
The advances in molecular biology and the emergence of Next Generation Sequencing
(NGS) have revealed that microbiome composition is closely related with health and
disease, including cancer. This relationship affects different levels of cancer such as
development, progression, and response to treatment including immunotherapy. The
efficacy of immune checkpoint inhibitors (ICIs) may be influenced by the concomitant
use of antibiotics before, during or shortly after treatment with ICIs. Nevertheless, the
linking mechanism between microbiote, host immunity and cancer is not clear and
the role of microbiota manipulation and analyses in cancer management has not been
clinically validated yet. Regarding the use of microbiome as biomarker to predict ICI
efficacy it has been recently shown that the use of biochemical serummarkers to monitor
intestinal permeability and loss of barrier integrity, like citrulline, could be useful to monitor
microbiota changes and predict ICI efficacy. There are still many unknowns about the role
of these components, their relationship with the microbiota, with the use of antibiotics
and the response to immunotherapy. The next challenge in microbiome research will
be to identify individual microbial species that causally affect lung cancer phenotypes
and response to ICI and disentangle the underlying mechanisms. Thus, further analyses
in patients with lung cancer receiving treatment with ICIs and its correlation with the
composition of the microbiota in different organs including the respiratory tract, peripheral
blood and intestinal tract could be useful to predict the efficacy of ICIs and its modulation
with antibiotic use.
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INTRODUCTION
Lung cancer is the most common cancer and the most frequent
cause of cancer-related deaths worldwide both in men and
women (1). Every year, more than 1.8 million people are
diagnosed with lung cancer, accounting for 1.6 million deaths
as a result of the disease. 5-year survival rates vary between
4 and 17% depending on stage and national differences (2).
Non-small cell lung cancer (NSCLC) accounts for 80%−90%
of lung cancers, while small cell lung cancer (SCLC) has been
decreasing in frequency in many countries over the past two
decades (1). Tobacco consumption represents one of the main
risk factors for lung cancer due to the presence of carcinogens
that promote cell transformation. However, other factors like
chronic inflammatory immune-mediated responses, genetic
predisposition or infections, like viral or more recently described
bacterial, have been involved in lung carcinogenesis (3).
The clinical management of this neoplasm has undergone
constant modifications, due to better knowledge of the biology
of the tumor and the genomic profile of each patient, which
allows a more accurate diagnosis and efficient treatment. During
the last few years, new therapies directed against molecular
targets involved in the regulation of the immune homeostasis and
cancer immunity have been incorporated, particularly immune
checkpoint inhibitors (ICIs), such as monoclonal antibodies
against the Programmed Cell Death Protein 1/Ligand 1 (PD1/L1)
axes or Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) (4). These
molecules are critical negative regulators of the immune system
that in physiological conditions prevent reactions against self-
antigens avoiding autoimmune reactions. Some tumors have
learnt to use these molecules to avoid immune attack and
perpetuate in the host, and thus, under specific situations
blocking ICs release these brakes and promote immune-mediated
tumor elimination.
ICIs are effective in locally advanced unresectable NSCLC
as consolidation after chemoradiotherapy (durvalumab) (5),
in patients with pretreated metastatic disease (nivolumab,
pembrolizumab, atezolizumab) (6–9) and also as first-
line treatment, both as monotherapy (pembrolizumab)
(10), in combination with chemotherapy (pembrolizumab,
atezolizumab) (11, 12) or as double immunotherapy (anti-PD1
nivolumab/anti-CTLA4 ipilimumab) (13). Recently it has also
been found to improve outcomes in metastatic SCLC as first line
treatment in combination with chemotherapy (atezolizumab,
durvalumab) (14, 15).
Despite these positive results, the major challenge that
clinicians face is the identification of those patients that will
benefit most from this therapy, including efficacy and low
toxicity. At present, the most commonly used biomarker
to predict ICIs efficacy, PDL1 expression, presents several
limitations (16).
In addition to prevent unwanted reactions against self-
antigens, ICIs are key molecules involved in the homeostatic
regulation of the immune response against commensal
microbiota. Thus, in recent years, microbiota has emerged
as critical regulator of the efficacy and toxicity of ICIs in different
types of cancer including lung. Here after a brief summary of
the main experimental evidences relating microbiota with lung
cancer development, we will discuss the relationship between the
composition of lung microbiota and the efficacy of ICIs and the
opportunities that this connection offers to exploit microbiome
analyses and modification in the prediction of ICIs efficacy (17).
Finally, we will present some of the main challenges that will be
required to overcome in order to use microbiota modification as
a therapeutic approach to enhance ICIs efficacy and safety.
MICROBIOTA AND TISSUE HOMEOSTASIS
The microbiota is emerging as a key regulator of cancer
development and treatment. From birth and throughout whole
life, the human beings keep an intimate mutually beneficial
relationship with the microbial community, using it as protection
against external aggressions and as a supplier of beneficiary
essential molecules.
The human microbiota is the ecological community of
commensal, symbiotic and pathogenic microorganisms,
including protozoa, fungi, bacteria, and viruses. Microbiota is
acquired after birth by vertical transmission inheritance from
the mother through direct surface contact, beginning shortly
after that its evolution (in response to environmental factors,
diet, drugs or environmental exposures) cumulating in a stable
adult microbiota by the age of two (18). Most studies have
been focused on the bacterial composition of microbiota, since
these microorganisms are the most abundant within commensal
microbiota. Indeed, it is estimated that a single human subject
harbors more than one billion bacterial cells, most of which are
commensal, so the total microbiota is estimated to constitute
0.2 kg of weight (19).
The size and the composition of the microbiota differ by
anatomical site, showing a wide interpersonal variation but
relatively temporal stability in a single individual (20). Thus,
the individual composition of microbiota should be taken into
account when using it as a biomarker for cancer treatment as well
as to design effective microbiota transplant protocols, which are
major current challenges in different pathologies including lung
cancer, as will be discussed in the next sections.
As indicated above, among other functions, microbiota
regulates host immunity and tissue homeostasis. Therefore,
the same microorganisms that are beneficial to human health,
under certain circumstances, can promote the development of
diseases and cancer (21–25). The eubiosis is conditioned by
multiple factors: hereditary and environmental factors, genetic
background, diseases, lifestyle (mainly diet), chronic infections
or antibiotic exposure, among others (26). These factors can
contribute to the perturbation of the balance of microbiota
composition, a situation known as dysbiosis. This situation can
be mild and temporal reverting after the detrimental stimulus is
removed. However, in some situations, this dysbalance can be
chronified, altering tissue homeostasis and leading to diseases
like cancer (25). Direct effects of microbial components on cell
transformation or indirect effects related with a dysregulated
inflammatory immune response have been found to be involved
in carcinogenesis (27).
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LUNG MICROBIOTA, CANCER AND
IMMUNOTHERAPY
The gut microbiota gives the major contribution to human
microbiota and comprises about 3× 1013 bacterial cells, followed
by the skin, which is estimated to harbor ∼1012 bacteria (28).
Accordingly, the intestinal microbiota and its role in regulating
host metabolism and gastrointestinal andmetabolic diseases such
as gastric cancer (29, 30), inflammatory bowel disease (a risk
factor for colorectal cancer), diabetes, and obesity (31–33) is the
most studied so far. However, recent findings indicate that other
microbial populations in the body like lungs are very important
in keeping tissue homeostasis and contribute to diseases like
asthma, COPD or lung cancer (27).
Lungs have traditionally been considered sterile space,
nevertheless they are constantly exposed tomicroorganisms since
the lower respiratory tract is replete with diverse communities
of bacteria both in health and in diseased states (34). Bacterial
communities in the lungs are dynamic as the airways are
constantly exposed to microorganisms suspended in the air that
flow through the oral cavity and upper respiratory tract to the
lower respiratory tract. The composition of lung microbiota
modulates a healthy host lung immune system. A proper
balance between lung immunity and microbiota is key to
fight infection but, in addition, to prevent lung inflammatory
diseases like cancer. The epithelial cell barrier is the first
line of defense in lungs preventing invasion by pathogenic
microbes and, at the same time, establishing key molecular
interactions with the commensal microbiota that regulates
immune homeostasis. Commensal microbiota regulates immune
tolerance, decreasing lung inflammation through dendritic cell
(DC), γδ T, and T regulatory (Treg) cell recruitment (27).
Other resident immune cells like macrophages, Innate Lymphoid
Cells (ILCs) and T cell subsets contribute to regulate local
inflammatory responses by preventing the overload of pathogens
or their metabolites. Lung microbiota dysbiosis can contribute
to cancer development by inducing a dysregulated immune
response characterized by an overactivation of inflammatory cells
like M1 macrophages, Th1 cells or γδ T cells. Inflammation
contributes to cell transformation and cancer by activating cell
proliferation pathways as well as by inducing radical oxygen
species and genetic mutations. The specific connection between
airway microbiota, immune regulation and lung cancer is not
clear yet. As an example it was recently shown that the presence
of a lung bacterial composition enriched in oral commensals is
associated with a prevalence of T helper 17 (Th17) inflammation
that seems to be key for a proper regulation of the lung immune
response (35). However, the connection between Th17 cells,
chronic lung inflammation and cancer is not yet clear.
Although less explored than the connection between
microbiota dysbiosis, chronic inflammation and cancer
development, microbial components can contribute to lung
cancer development by producing metabolites with oncogenic
potential. For example, Tsay et al. (36) found that exposure
to Veillonella, Prevotella, and Streptococcus bacteria induce
epithelial cell transformation in vitro and in vivo by activating
the PI3K and ERK pathways.
The respiratory microbiome differs significantly between the
three major anatomical regions: oral/nasal, upper and lower
respiratory tract (37). Taking into account the communication
between the oral cavity and the respiratory tract, the oral
microbiome could be highly relevant to the lung microbiome.
Nevertheless, not every alteration observed in sputum represents
changes in themicrobiome of the lower airwaymicrobiome, since
there is increasing evidence that the microbiome of sputum is a
better reflection of the oral microbiome than of the lower airway
microbiome (38–40).
Movement of microbes between these sites and the lungs
occurs regularly via breathing and microaspiration of pharyngeal
secretions, which seems to be the main source of lung microbiota
in healthy subjects (41). Despite this connection, it should be
considered that the composition and function of upper and
lower airways microbiome are not identical and (37), thus, these
differences should be had in mind to design studies that can be
successfully applied to the diagnosis and treatment of cancer.
For example, identification of microbiome composition in oral
cavity or saliva could be useful to identify biomarkers to predict
ICI response, but when designing interventions to modulate
lung microbiota composition and enhance ICIs efficacy, genuine
identification of lung microbiota might be required.
Several sample types are used to analyzed lung microbiome
composition: bronchoalveolar lavage (BAL), bronchial brushing
tissue, buccal sample, surgical resection tissue or exhaled
breath condensate (23, 42), among others. Large number
of samples, use of non-invasive studies, and exact statistical
analysis are crucial for detection of predominant bacterial
species in lung cancer (43). Because of the mentioned
technical reasons, characterization of the oral microbiome is
less complex than characterization of lung microbiome. The
oral microbiota includes bacteria, fungi, as well as viruses. It
has been associated with systemic diseases including infective
endocarditis, rheumatoid arthritis, pulmonary disease, and in
more recent studies, with cancer (44–46). It is important to take
into account that the oral microbiota can aid in conversion of
alcohol and smoking byproducts to mutagenic compounds, so
that the oral dysbiosis may be related to premalignant processes
and the cancer itself (34). Thus, analyses of oral microbiota might
also be interesting to find out predictive biomarkers for ICI or
even to modulate its composition to prevent cancer development
or progression or to enhance ICI efficacy.
The number of studies in the field of lung microbiota is
rapidly growing and have yielded provocative observations
highlighting a possible relationship between lung microbiota and
respiratory disease (23). The development of lung cancer seems
to be closely associated with chronic inflammation characterized
by infiltration of inflammatory cells and accumulation of
pro-inflammatory factors (cytokines, chemokines, and
prostaglandins), a high bacterial load and linked to airway
dysbiosis or reduction in the dominant bacterial species in the
microbiota (37, 47–49).
Specific microbes have been associated with lung
cancer (Pseudomona, Veillonella, Streptococcus, Provotella,
Fusobacteria. . . ) (50, 51) as Bacteroides, Firmicutes, and
Proteobacteria are the most common phyla consistently observed
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in lung microbiota of healthy individuals (23, 52). Higher
richness and diversity in normal tissue seems to be significantly
associated with reduced recurrence-free and disease-free
survival. Family Lachnospiraceae, genera Faecalibacterium
and Ruminococcus, among others, are associated with reduced
recurrence-free and disease-free survival (53).
Paramount to the development of microbiota-based
therapeutics, the next challenge in microbiome research
will be to identify individual microbial species that causally affect
cancer phenotypes and unravel the underlying mechanisms (54).
Metagenomics studies using culture-independent techniques
such as PCR amplification and sequencing of the 16S ribosomal
(r)RNA gene, especially variable regions V3-V4 of 16S rRNA
bacterial gene sequencing, enables the identification and
classification of the species without requiring pre-cultivation
(25, 55). The sequencing of basal stool and saliva samples from
patients treated with ICIs has obtained striking preliminary
results that suggest a close relationship between the commensal
microbiome and the clinical efficacy of immunotherapy,
which might be useful to stratify patients based on their
metagenomic microbial fingerprint (28). However, it should be
taken into account that rRNA sequencing has limitations since
it cannot differentiate between living and dead microbes. Thus,
metagenomic analyses just provide the picture of the microbial
composition (microbiome) without providing information on
the potential functional consequences of those microbes. Here
the analyses of genes expressed by the microbial community
(metatranscriptomics) and their byproducts (metabolomics)
can be very useful since they provide information on the
functional state of microbiota and the potential consequences
for the health of the environmental niche they inhabit, the
lung in this case. Thus, the combination of metagenomics,
metatranscriptomics, and metabolomics will provide a whole
picture on the composition of lung microbiota and their
functional consequences under different conditions (56).
ICIs act by blocking pathways of negative regulation
of the immune system, in order to enhance antitumor
immune response. Due to the general dysregulation of immune
homeostasis, ICIs induce a broad spectrum of side effects
potentially involving any organ, known as immune-related
adverse events (irAEs) (57). irAEs occur more commonly in
patients on anti-CTLA- 4 treatment as compared with those
taking anti-PD-1/-L1, and the incidence of irAEs increases when
these agents are used in combination. It has been reported that
patients who receive ICIs and have immuno-related toxicity
(58, 59) have a different intestinal microbiota composition, in
addition to a possible greater benefit of treatment (60, 61). Thus,
further studies correlating these factors are of interest in order to
establish microbiome composition as a predictive biomarker for
ICI efficacy and toxicity.
There are multiple studies exploring the possibility that
dysbiosis associated with malignant disease or concomitant
antibiotic use (before, during or shortly after treatment with ICIs)
could influence ICI efficacy. NSCLC patients taking antibiotic
during ICI treatment have a significant reduction in progression
free survival and overall survival compared with those who
did not receive antibiotics (62). Here it should be taken into
consideration that antibiotic use might be associated with a
more severe disease and thus, this might act as a confounding
factor when studying the correlation between antibiotic and ICI
efficacy. Although most studies have focused on the intestinal
microbiota, it is expected that antibiotics could also influence
the lung microbiota, altering the antitumoral effect of ICIs, anti-
CTLA4 and anti-PD-1 / L1 in patients with lung cancer (63).
MUCOSAL BARRIER INTEGRITY AND
MICROBIOTA
Gut and lung microbiota are connected thanks to a complex
bidirectional axis via lymphatic and blood circulation, whichmay
explain why changes in one mucosal compartment could directly
impact a distant mucosal site (64).
Gut microbes can influence lung immune function through
different mechanisms. One would be the connection through
molecular patterns associated with pathogens, such as
lipopolysaccharides (LPS), which can stimulate toll-like
receptors and activate genes that regulate inflammation and
responses of the innate immune system. In addition, they
would cause phenotypic changes in dendritic cells (DCs) and
migration to mesenteric lymphoid nodes to promote the priming
of T lymphocytes and the production of various regulatory
cytokines (IL-10, TGF-β, IFNγ, and IL-6). In these lymph nodes,
T cells acquire localization molecules that initiate migration to
the respiratory mucosa, through CCR4 or CCR6, where they
promote protective and anti-inflammatory responses. Another
mechanism would be metabolites such as short chain fatty acids
(SCFA), produced by the fermentation of carbohydrates by
bacteria, which modify gene expression through the inhibition
of histone deacetylases, methylation, the production of cytokines
and chemokines, and cell differentiation, proliferation and
apoptosis (18, 65–67).
Intestinal dysbiosis leads to perturbation of gut immune
homeostasis favoring the development of inflammatory processes
and even tumoral processes (30, 57). The permeability of the
epithelial barriers, like intestinal and respiratory tract, is closely
related to the luminal content and the interaction with the
microbiota. Permeability depends on the junctional complex
between the intestinal enterocytes, which includes tight junction
(TJ) proteins that regulate the transport of ions and water
between the gut lumen and the blood stream. Increased gut
permeability causes the trespass of antigens to the lamina
propia and the blood stream, promoting a local and systemic
inflammatory immune responses enhancing epithelial barrier
loss and affecting distant organs and tissues (68). The protein
zonuline is an admissible regulator of TJs permeability and the
only known physiological regulator of intestinal TJs, and its
presence in serum has been proposed as a peripheral marker
to assess gut permeability (69), as well as endotoxin. (70, 71).
Thus, the loss of barrier function may be suspected by a
positive zonuline regulation (68, 72–74). However, there are
many unknowns about the role of these components, their
relationship with the microbiota, with the use of antibiotics and
with the response to immunotherapy. In addition, it has been
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recently shown that detection of zonuline in serum might be
affected by serious technical flaws and thus its value to monitor
epithelial barrier permeability should be confirmed (75).
On the other hand, plasma citrulline, an amino acid produced
by enterocytes, has been validated as a marker of the intestinal
barrier and function of enterocytes. Citrulline can be produced
as a result of a post-transduction modification from arginine
in a reaction catalyzed by peptidyl-arginine deaminase. This
modification occurs in inflammatory processes and cell death.
In these processes, citrulline can be recognized aberrantly by
the immune system, leading to the generation of anti-citrulline
antibodies. Under some circumstances, such as infections and
the need for antibiotic treatment in patients with lung cancer
undergoing treatment with ICIs, inflammatory phenomena and
cell death may occur leading to aberrant recognition of citrulline
and the generation of anti-citrulline antibodies. Finally, it seems
that citrulline levels are affected with the use of antibiotics
and can be correlated with the response to immunotherapy
(76). Identification of soluble circulating factors that might be
markers of the integrity of the epithelial barrier could be very
useful to monitor cancer progression and treatment efficacy as
discussed below.
Several studies have studied the correlation between gut
microbiome and outcomes to ICIs. A greater diversity of
the intestinal microbiome seems to be related to a greater
progression-free survival (77), showing a higher concentration of
Akkermansia muciniphilia in the stools of the responders (62).
CHALLENGES AND FUTURE
PERSPECTIVES
Understanding how microorganisms present in the respiratory
tract can influence the development of lung carcinoma and
the effectiveness of treatments is key to develop therapeutic
approaches to modify the microbial composition and thus
improve their effectiveness.
Future precision medicine strategies will likely be based on
new diagnostic and therapeutic tools that identify alterations
in the microbiome in each patient that could be used as new
biomarkers for individual treatments (28). These biomarkers
could also help identify candidate patients for microbiota
intervention strategies such as fecal microbiota transplantation
(FMT) with the possibility of evaluating the effects of selected
members of the commensal gut microbiota on systemic
immunity, including in the lungs, as well as the use of probiotics
and prebiotics (78, 79). FMT, usually used to treat recurrent
Clostridium difficile infection, could be used as therapy to treat
other diseases related to an unhealthy gut microbiota. However,
before implementing these approaches it should be clarified
how to prepare patients for FMT (preconditioning) and how
to manage possible complications related to antibiotic resistance
and the potential of infections due to FMT.
The modulation of microbiota is considered a relevant target
for novel therapeutic and preventive treatments against a range
of diseases (70), albeit this field is still in its infancy and more
research is required before microbiota can be safely manipulated
to prevent or treat disease. The microbiome may be potentially
manipulated with an aim to correct dysbiosis through nutritional
interventions such us use of probiotics, prebiotics or antibiotics,
among others, seeking for a reversion of immunosuppression
present in the tumor microenvironment (80). For example it has
been found that oral administration of Bifidobacterium induces
dendritic cell function and increases CD8+ T cell accumulation
in the tumor microenvironment, improving response to anti-
PDL1 antibody in mouse models of cancer (81). Despite some
advances, caution is warranted as the ideal beneficial lung
microbiota and how to change it as well as the potential
risks of this modification are not yet known. For example,
uncontrolled microbiota manipulation might induce detrimental
inflammatory reactions that could worsen rather than improve
cancer evolution and treatment efficacy.
Several studies have supported that the lung microbiota may
play a key role in carcinogenesis and in response to chemotherapy
and immunotherapy. Gut microbiome is the most studied so
far. Lung microbiome is currently being studied to determine
how and when does it affect lung cancer development and
the best techniques to analyze it. New techniques based on
microbiota-associated metabolic fingerprints can be useful to
identify microbiota composition as recently developed for gut
microbiota from lung cancer patients without requiring RNA
analyses (82). Notably, it has been found that the metabolic
profile in lungs from diseased patients, including lung cancer,
significantly differs from that in healthy individuals (83–85).
Notably some studies have found that specific metabolites are
enriched in respiratory airways of patients with different diseases
and this profile correlates with the presence of specific bacterial
species (86–88).
These results indicate that characterization of lung
metabolome could be used as a surrogate marker of changes
in lung microbiota in order to provide an easier and more
robust technology to use lung microbiota (or their products)
as a biomarker for diagnosis and immunotherapy response
in lung cancer. A recent study found that the presence of
specific microbial metabolites in plasma correlated with
anti-PD1 efficacy in lung cancer patients (89). Although
similar studies have not been performed yet in airways, a
recent study has shown that the profile of Volatile Organic
Compounds in exhaled breath from lung cancer patients
determined using an electronic nose predicts the efficacy
of anti-PD1 treatment (90). Although future studies will be
required to characterize the origin of these metabolites (host
and/or microbial) and its correlation with changes in airway
microbial composition and the response to anti-PD1 therapy,
this approach would be very useful to implement the use of
airway microbiota in clinical management of lung cancer and
immunotherapy treatment.
Analysis of the upper respiratory tract microbiota as the
source of the lung and gastric microbiota could be useful
if the correlation between both (oral/upper respiratory tract
and lung/gut) would be demonstrated. The sampling would
be facilitated by less invasive techniques for the patient (nasal
smears, saliva samples...), with the possibility of evaluating the
changes over time.
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The study of the microbiota is a field that has just made
its way, offering opportunities and challenges for improving
immunotherapy efficacy. Our group is conducting a pilot study in
this direction in lung cancer patients receiving immunotherapy.
OUTSTANDING QUESTIONS
1. Can we use antibiotics to safely modulate the microbiota?
How can we modify resistant bacteria’s composition
and achieve the proper balance? What are the risks of
microbiota manipulation?
2. What conditioning does a patient require prior to a fecal
microbiota transplant? What is the proper composition for
each individual?
3. Would it be useful to have an individualized microbiota bank?
4. Which barrier is primarily responsible for the loss of epithelial
barrier in lung cancer? Are there specific markers that allow us
to differentiate them?
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